Net Loss Per Share Attributable to Common Stockholders (Tables)

9 Months Ended

Sep. 30, 2021

Earnings Per Share [Abstract]

Weighted-Average Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share as They Had Anti-Dilutive Effect

The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share for the periods presented as they had an anti-dilutive effect:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
Options to purchase common stock		1,141,224		850,716		1,008,663		742,797
Contingently issuable common stock prior to exchange of    Vaccinex Products, LP units		-		1,163,141		742,705		1,170,047
Contingently issuable common stock prior to exchange of    VX3 units		-		1,318,797		817,167		1,318,797